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The 2009 pandemic influenza has provided a unique opportunity to learn about 
influenza. Dose-sparing intradermal vaccination has been found to be effective in 
seasonal influenza [1]. However, this strategy has not been tested for the pandemic 
influenza. We therefore performed a prospective, randomized, open-label, single-
centre trial from January to March 2010, to compare the safety and immunogenicity 
between conventional full-dose intramuscular (IM) and low-dose (20%) intradermal 
(ID) immunizations of the monovalent 2009 H1N1 vaccine in chronically ill adults.  
 
Patients were randomized to receive a single low-dose (3µg hemagglutinin) ID 
vaccination or a single full-dose (15µg) IM vaccination. The vaccine used was 
Panenza® (Sanofi-Pasteur, France), a monovalent inactivated, non-adjuvanted 
vaccine formulated to contain 15µg of hemagglutinin of influenza 
A/California/07/2009 virus. Antibody titers were measured using hemagglutination-
inhibition (HAI) and microneutralization (MN) assays according to standard methods 
[2], at baseline, 21 and 42 days after vaccination. Avidity testing was performed by 
comparing the optical density after urea treatment in an ELISA assay [3]. Safety was 
assessed by the vaccinees completing the immediate adverse event checklist and a 7-
day diary.  
 
A total of 37 subjects (ID:18 and IM:19) were enrolled. Two subjects in the IM group 
were lost to follow-up. Baseline demographics between the two groups were well 
matched. No deaths or serious adverse events were reported. Local symptom of post 
vaccination erythema was significantly more common in the ID group while other 
local and systemic symptoms were reported in similar frequency in both groups. 
There was no significant difference in seroconversion and seroprotection rates by 
either assay (Table 1) between the two groups on day 21 [HAI seroconversion and 
seroprotection: ID vs. IM: 27.78% vs. 29.41% (p=1.00)] and day 42 [HAI 
seroconversion and seroprotection: ID vs. IM: 38.89% vs. 35.29% (p=1.00)]. The 
geometric-mean-titer (GMT) fold increase by HAI on day 21 in both groups met the 
criteria defined by the Committee for Proprietary Medicinal Products (CPMP) [GMT 
fold increase value (95% C.I.): ID vs. IM: 11 (-3.71-25.71) vs. 6.53 (2.12-10.94) 
(p=1.00)]. There was no correlation between post-vaccination erythema and 
subsequent seroconversion/ seroprotection rate on day 21 or 42 (p>0.05). Antibody 
avidity testing (Table 1) showed no significant difference between the two groups, 
and between the day 21 and 42 samples. 
 
 
This is the first intradermal 2009 H1N1 vaccine evaluation. Data from this study 
suggested that immunogenicity of the monovalent H1N1 2009 vaccine was lower than 
previously published results for similar unadjuvanted 15µg split virus vaccines [4]. 
This could be attributed to population selection (patients with chronic diseases or 
elderly) or high pre-immunization antibody response [5]. Adjuvants or booster dose 
should be considered to generate satisfactory immunogenicity [4]. The limitation of 
this study is the lack of appropriate sample size secondary to the widely report of an 
unrelated post vaccinee who developed Guillain-Barre syndrome, discouraging 
potential vaccinees who may benefit from this vaccine. In conclusion, dose sparing 
intradermal influenza vaccination is safe and effective and should be encouraged in 
elderly and immunosuppressed patients. This strategy should be incorporated in the 
pandemic preparedness plans globally.  
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Table 1. Immunogenicity by hemagglutination-inhibition and microneutralization 
assays  
  
  ID IM P- value 
Hemagglutination- 
Inhibition 
    
  GMT values (95% CI) Day 0 7.08 (5.56-
9.02) 
6.14 (5.2-7.26)  
 Day 21 22.39 (11.25-
44.57) 
21.63 (11.56-
40.46) 
 
 Day 42 23.27 (11.52-
46.97) 
17.66 (8.86-
35.23) 
 
     
  CPMP criteria (day 21) Seroconversion (%) 27.78 29.41 1.00 
 Seroprotection (%) 27.78 29.41 1.00 
 GMT fold increase value 
(95% CI) 
11 (-3.71-
25.71) 
6.53 (2.12-
10.94) 
 
     
  CPMP criteria (day 42) Seroconversion (%) 38.89 35.29 1.00 
 Seroprotection (%) 38.89 35.29 1.00 
 GMT fold increase value 
(95% CI) 
11.25 (-3.43-
25.93) 
5.88 (1.58-
10.18) 
 
     
Microneutralization 
 
    
  GMT values (95% CI) Day 0 12.11 (9.12-
16.11) 
10.84 (8.77-
13.43) 
 
 Day 21 22.39 (12.39-
40.46) 
25.47 (12.79-
50.85) 
 
 Day 42 25.12 (13.46-
46.88) 
29.92 (15.60-
57.54) 
 
     
  CPMP criteria (day 21) Seroconversion (%) 16.67 29.41 0.443 
 Seroprotection (%) 27.78 29.41 1.00 
 GMT fold increase value 
(95% CI) 
3.81 (0.14-
7.47) 
5.54 (1.21-
9.87) 
 
     
  CPMP criteria (day 42) Seroconversion (%) 22.22 35.29 0.315 
 Seroprotection (%) 38.89 35.29 1.00 
 GMT fold increase value 
(95% CI) 
4.06 (1.28-
6.83) 
4.97 (2.02-
7.92) 
 
     
Avidity Testing 
 
    
Mean Antibody Index 
(SEM) 
Day 21 18.97 (1.99) 15.93 (8.1) 0.285 
Day 42 17.07 (1.35) 16.78 (2.35) 0.912 
ID: intradermal group; IM: intramuscular group. GMT: geometric mean titer; CPMP: Committee for 
Proprietary Medicinal Products; SEM: standard error of the mean CPMP guideline: at least one of the 
following criteria must be met for the viral strain in the vaccine: GMT fold increase >2.5, 
seroconversion rate >40% and seroprotection rate > 70% 
